# FDA Approves Sacituzumab Govitecan (Trodelvy) as First-Line Monotherapy and Combo Therapy for Unresectable Metastatic TNBC

> fda · REPORTED · 2026-06-24

On June 24, 2026, the FDA approved sacituzumab govitecan-hziy (Trodelvy) for two first-line indications in adults with unresectable locally advanced or metastatic triple-negative breast cancer, including as a single agent and in combination with pembrolizumab for PD-L1-positive TNBC, supported by the ASCENT-03 trial.

About Gilead Sciences / Trodelvy: Gilead Sciences is a global biopharmaceutical company, and Trodelvy (sacituzumab govitecan) is its antibody-drug conjugate targeting TROP-2, approved for breast and urothelial cancers.

- Company: Gilead Sciences / Trodelvy
- Sector: oncology
- Primary source: https://nnecos.org/fda/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.